Silence Therapeutics (XRP2) Stock Forecast & Price Target

Compare

36 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XRP2 Analyst Ratings

Moderate Buy

4 Buy

0 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Silence

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XRP2 Stock 12 Month Forecast

Average Price Target

€25.24

▲(376.28% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is €25.24 with a high forecast of €65.51 and a low forecast of €3.49. The average price target represents a 376.28% change from the last price of €5.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","66":"€66","17.25":"€17.25","33.5":"€33.5","49.75":"€49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65.50876275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€65.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.242709913,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€25.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.49380068,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,17.25,33.5,49.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,9.026827903846154,13.733655807692308,18.440483711538462,23.147311615384616,27.85413951923077,32.560967423076924,37.26779532692308,41.97462323076923,46.681451134615386,51.38827903846154,56.095106942307694,60.80193484615385,{"y":65.50876275,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,5.929439224076923,7.538878448153846,9.14831767223077,10.757756896307692,12.367196120384614,13.976635344461538,15.58607456853846,17.195513792615383,18.804953016692306,20.414392240769228,22.02383146484615,23.633270688923076,{"y":25.242709913,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.256446206153846,4.1928924123076925,4.129338618461539,4.065784824615385,4.002231030769231,3.938677236923077,3.875123443076923,3.811569649230769,3.7480158553846152,3.6844620615384613,3.620908267692308,3.557354473846154,{"y":3.49380068,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.86,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 91, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€65.51

Average Price Target€25.24

Lowest Price Target€3.49

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

€65.51

Buy

1136.01%

Upside

Reiterated

03/13/26

Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN)

Myles Minter

William Blair

€4.8

Buy

-9.36%

Downside

Reiterated

03/06/26

Silence Therapeutics: Pipeline Resilience and Upcoming Clinical Catalysts Support Buy Rating Despite AstraZeneca Exit

Michael Ulz

Morgan Stanley

€21.84

Buy

312.00%

Upside

Reiterated

03/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), RxSight (NASDAQ: RXST) and Compass Therapeutics (NASDAQ: CMPX)

Keay Nakae

Chardan Capital

€30.57

Buy

476.81%

Upside

Reiterated

03/05/26

Chardan Capital Keeps Their Buy Rating on Silence Therapeutics (SLN)

Richard Law CFA

Goldman Sachs

€3.49

Sell

-34.08%

Downside

Reiterated

03/05/26

Goldman Sachs Reaffirms Their Sell Rating on Silence Therapeutics (SLN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

€65.51

Buy

1136.01%

Upside

Reiterated

03/13/26

Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN)

Myles Minter

William Blair

€4.8

Buy

-9.36%

Downside

Reiterated

03/06/26

Silence Therapeutics: Pipeline Resilience and Upcoming Clinical Catalysts Support Buy Rating Despite AstraZeneca Exit

Michael Ulz

Morgan Stanley

€21.84

Buy

312.00%

Upside

Reiterated

03/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), RxSight (NASDAQ: RXST) and Compass Therapeutics (NASDAQ: CMPX)

Keay Nakae

Chardan Capital

€30.57

Buy

476.81%

Upside

Reiterated

03/05/26

Chardan Capital Keeps Their Buy Rating on Silence Therapeutics (SLN)

Richard Law CFA

Goldman Sachs

€3.49

Sell

-34.08%

Downside

Reiterated

03/05/26

Goldman Sachs Reaffirms Their Sell Rating on Silence Therapeutics (SLN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Silence Therapeutics

3 Months

xxx

Success Rate

11/17 ratings generated profit

Average Return

+9.85%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +9.85% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

11/17 ratings generated profit

Average Return

+2.66%

reiterated a buy rating 18 days ago

Copying Myles Minter's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +2.66% per trade.

2 Years

xxx

Success Rate

11/22 ratings generated profit

Average Return

-5.35%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -5.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XRP2 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

109

In the current month, XRP2 has received 7 Buy Ratings, 91 Hold Ratings, and 11 Sell Ratings. XRP2 average Analyst price target in the past 3 months is 25.24.

Each month's total comprises the sum of three months' worth of ratings.

XRP2 Financial Forecast

XRP2 Earnings Forecast

Next quarter’s earnings estimate for XRP2 is -€0.11 with a range of -€0.24 to -€0.07. The previous quarter’s EPS was -€0.08. XRP2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.

XRP2 Sales Forecast

Next quarter’s sales forecast for XRP2 is €1.09M with a range of €0.00 to €5.20M. The previous quarter’s sales results were €29.44K. XRP2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.

XRP2 Stock Forecast FAQ

What is DE:XRP2’s average 12-month price target, according to analysts?

Based on analyst ratings, Silence Therapeutics’s 12-month average price target is 25.24.

What is DE:XRP2’s upside potential, based on the analysts’ average price target?

Silence Therapeutics has 376.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Silence Therapeutics a Buy, Sell or Hold?

Silence Therapeutics has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 0 hold ratings and 1 sell ratings.

What is Silence Therapeutics’s share price target?

The average share price target for Silence Therapeutics is 25.24. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €65.51 ,and the lowest forecast is €3.49. The average share price target represents 376.28% Increase from the current price of €5.3.

What do analysts say about Silence Therapeutics?

Silence Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Silence Therapeutics?

To buy shares of DE:XRP2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Silence Therapeutics (XRP2) Stock Forecast & Price Target

XRP2 Analyst Ratings

XRP2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Silence Therapeutics

XRP2 Analyst Recommendation Trends

XRP2 Financial Forecast

XRP2 Earnings Forecast

XRP2 Sales Forecast

XRP2 Stock Forecast FAQ

Detailed List of Analyst Forecasts